Do we know if the 'autologous dendritic cell immunotherapy' employed in the study you quoted was in fact DCVax?
If so, then it would be the first study that I am aware of where DCVax effectiveness against liver cancer has been demonstrated (albeit in a mice model).
The breadth of application for DCVax is really quite exciting.
Yes, that is it but.. for long term control sufficient time (length of treatment regimen)is required with properly activated DCs maintained on location (interval spacing of injections) to achieve immune memory of T-cells and B cells and complete eradication of the tumor. Without this, overpowering immunosuppression returns for most patients that did not have a sufficiently initial robust response.